Annals of Oncology

In this issue:

In this issue
Ann Oncol 3: 1.
[PDF] [Request Permissions]

Contents of the next issue:

Contents of the next issue
Ann Oncol 3: 1.
[PDF] [Request Permissions]

NEWS:

First Horten Prize to Doll and Peto
Ann Oncol 3: 2.
[PDF] [Request Permissions]

Steven Dickman

Clinical cancer research: Cancer treatment from the ‘Red Baron’ Dresden
Ann Oncol 3: 2-4.
[PDF] [Request Permissions]

Free enterprise, nurses and ethical problems in Maastricht
Ann Oncol 3: 4-5.
[PDF] [Request Permissions]

Europeans still undecided on chemoprevention for breast cancer
Ann Oncol 3: 5-6.
[PDF] [Request Permissions]

Underground production of cytotoxic drugs?
Ann Oncol 3: 6.
[PDF] [Request Permissions]

ESMO Award Lecture coupled with Oliva Prize
Ann Oncol 3: 6.
[PDF] [Request Permissions]

Perhaps not everyone knows that...
Ann Oncol 3: 6-7.
[PDF] [Request Permissions]

Editorials:

F. Cavalli

The Annals continues to grow
Ann Oncol 3: 8.
[PDF] [Request Permissions]

K. Østerlind and H. H. Hansen

Ways to a better treatment of small cell lung cancer—a commentary
Ann Oncol 3: 9-10.
[PDF] [Request Permissions]

Special articles:

J.-C. Cerottini, V. von Fliedner, and T. Boon

Recognition of tumor-associated antigens by T lymphocytes: From basic concepts to new approaches
Ann Oncol 3: 11-16.
[PDF] [Request Permissions]

Review:

J. P. Neijt

Treatment of advanced ovarian cancer: 10 years of experience
Ann Oncol 3: 17-27.
[Abstract] [PDF] [Request Permissions]

Arena:

B. A. Stoll

Does extra height justify a higher risk of breast cancer?
Ann Oncol 3: 29-30.
[Abstract] [PDF] [Request Permissions]

Original articles:

E. Alba, J. J. Breton, L. Alonso, G. Paredes, J. Belon, and P. Ballesteros

Alternating chemotherapy for small-cell lung cancer. A twelve-week schedule of six drugs
Ann Oncol 3: 31-35.
[Abstract] [PDF] [Request Permissions]

C. F. Krommer and J. P. Szalai

Cyclophosphamide, Adriamycin and Cisplatin (CAP) versus Cyclophosphamide, Adriamycin and Vincristin (CAV) in the treatment of advanced ovarian cancer: A randomized study
Ann Oncol 3: 37-39.
[Abstract] [PDF] [Request Permissions]

P. P. B. James and G. M. Mead

Sanctuary site relapse in chemotherapy-treated testicular cancer
Ann Oncol 3: 41-43.
[Abstract] [PDF] [Request Permissions]

S. M. Ansell, G. Falkson, R. van der Merwe, and A. Uys

Chronological age is a multifactorial prognostic variable in patients with Non-Hodgkin's Lymphoma
Ann Oncol 3: 45-50.
[Abstract] [PDF] [Request Permissions]

M. Soesan, A. Paccagnella, V. Chiarion-Sileni, L. Salvagno, A. Fornasiero, G. Sotti, P.-L. Zorat, A. Favaretto, and M. Fiorentino

Extramedullary plasmacytoma: Clinical behaviour and response to treatment
Ann Oncol 3: 51-57.
[Abstract] [PDF] [Request Permissions]

B. Leyland-Jones, B. R. Davies, K. Clagett-Carr, D. Shoemaker, D. Macfarlane, C. Fortner, P. J. O'Dwyer, G. Sarosy, B. J. Foster, H. G. Chun, D. E. Hoth, and L. V. Rubinstein

Patient treatment on a compassionate basis: Documentation of high adverse drug reaction rate
Ann Oncol 3: 59-62.
[Abstract] [PDF] [Request Permissions]

G. Toffoli, S. Frustaci, L. Tumiotto, R. Talamini, F. Gherlinzoni, P. Picci, and M. Boiocchi

Expression of MDR1 and GST- in human soft tissue sarcomas: Relation to drug resistance and biological aggressiveness
Ann Oncol 3: 63-69.
[Abstract] [PDF] [Request Permissions]

L. Damstrup, J. Andersen, D. W. Kufe, D. F. Hayes, and H. Skovgaard Poulsen

Immunocytochemical determination of the estrogen-regulated proteins M_r 24, 000, M_r 52, 000 and DF3 breast cancer associated antigen: Clinical value in advanced breast cancer and correlation with estrogen receptor
Ann Oncol 3: 71-77.
[Abstract] [PDF] [Request Permissions]

Book reviews:

N. de Tribolet

Book review
Ann Oncol 3: 40.
[PDF] [Request Permissions]

A. Pedrazzini

Book review
Ann Oncol 3: 44.
[PDF] [Request Permissions]

C. Sessa

Book review
Ann Oncol 3: 58.
[PDF] [Request Permissions]

C. Bosia

Book reviews
Ann Oncol 3: 70.
[PDF] [Request Permissions]

Short reports:

E. E. Vokes, D. J. Haraf, J. M. McEvilly, R. Mick, M. F. Kozloff, M. D. Goldman, W. J. Moran, N. J. Clendeninn, M. A. Collier, R. R. Weich selbaum, and W. R. Panje

Neoadjuvant PFL augmented by methotrexate and piritrexim followed by concomitant chemoradiotherapy for advanced head and neck cancer: A feasible and active approach
Ann Oncol 3: 79-81.
[Abstract] [PDF] [Request Permissions]

B. Weinerman, E. Eisenhauer, D. Stewart, W. Mertens, I. Tannock, P. Venner, and R. Spaulding

Phase II study of sulofenur (LY186641) in measurable metastatic renal cancer
Ann Oncol 3: 83-84.
[PDF] [Request Permissions]

N. A. Pavlidis, E. Briassoulis, G. Klouvas, and M. Bai

Is interferon-a an active agent in Castleman's disease?
Ann Oncol 3: 85-86.
[PDF] [Request Permissions]

Letters:

A. Martoni, A. Cricca, M. Guaraldi, M. Covizzi, A. Farris, and F. Pannuti

Randomized clinical trial with a weekly regimen of 5-FU vs 5-FU + intermediate-dose folinic acid in the treatment of advanced colo-rectal cancer
Ann Oncol 3: 87-88.
[PDF] [Request Permissions]

A. Thyss, M. H. Gaspard, R. Marsault, G. Milano, C. Frelin, and M. Schneider

Very high endothelin plasma levels in patients with 5-FU cardiotoxicity
Ann Oncol 3: 88.
[PDF] [Request Permissions]

Instructions to Authors:

Instructions to Authors
Ann Oncol 3: 89-90.
[PDF] [Request Permissions]

To see an article, click its [Full Text] or [PDF] link. To review many abstracts, check the boxes to the left of the titles you want, and click the 'Get All Checked Abstract(s)' button. To see one abstract at a time, click its [Abstract] link.